<DOC>
	<DOCNO>NCT00177528</DOCNO>
	<brief_summary>This research study evaluate safety usefulness venlafaxine-XR treatment major depression elderly .</brief_summary>
	<brief_title>Safety Efficacy Venlafaxine XR Elderly Patients With Major Depression</brief_title>
	<detailed_description>The primary objective pilot study evaluate safety venlafaxine extend release formulation ( XR ) treatment geriatric non-psychotic depression . This pilot study 's specific aim assess safety venlafaxine XR geriatric population , estimate response rate old depressed subject treat open condition evaluate pharmacokinetic characteristic may impact safety outcome .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<criteria>men woman race 60 year old old ; DSMIV diagnosis major depressive episode without psychotic feature ; 17item HamD score &gt; 15 potential subject receive antidepressant treatment illness episode HAMD &gt; 11 potential subject receive treatment antidepressant ( venlafaxineXR ) illness episode ; MMSE score &gt; 15 . history meeting DSMIV criterion mania , schizophrenia psychotic disorder ; history substance abuse dependence , include alcohol , within last three month ; current hyponatremia ( define serum sodium level &lt; 130 meq/l ) ; untreated uncontrolled hypertension ; history unable tolerate venlafaxineXR venlafaxine immediate release formulation ; history receive venlafaxineXR venlafaxine immediate release formulation 6 week 300mg/d index depressive episode ; ( 7 ) EKG reveal QTc &gt; 480 msec ; myocardial infarction , unstable angina , palpitation cardiogenic syncope within 3 month prior enter study ; presence active suicidal ideation intent .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Elderly</keyword>
</DOC>